glp-1 inhibitors receptor agonists for individualized treatment of type 2 diabetes mellitus GLP-1 Receptor Agonists Among Patients

Technologies such as AI and machine learning are set to revolutionize early detection and personalized treatment plans

Antioxid Basel Switz

W: Sample weight, g

The Study: Real-World Weight Loss Outcomes Researchers analyzed data from over 50,000 adults with obesity: 38,545 patients received a GLP-1 medication such as semaglutide or tirzepatide 12,540 patients underwent bariatric surgery, primarily gastric bypass or sleeve gastrectomy Key Findings : Surgery patients lost an average of 24% of their body weight over two years about 58 pounds

Recombinant CCP1-2 of the C4bp -chain was expressed and purified as described previously (37), with some adaptations

Stylianopoulos, T., Martin, J